StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

Investment analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued on Sunday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Stock Down 2.4 %

Shares of TXMD stock opened at $1.22 on Friday. TherapeuticsMD has a fifty-two week low of $1.15 and a fifty-two week high of $2.75. The firm’s 50 day moving average price is $1.46 and its two-hundred day moving average price is $1.68.

Institutional Trading of TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP boosted its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the period. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent reporting period. 30.74% of the stock is currently owned by institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.